Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MALT1 | Q9UDY8 | 7/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567590 | 0.86 | NPC1 (0.70) | SMN1; SMN2MALT1EPHX2NPC1TSHR | |
| SCHEMBL10211682 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2NPSR1MALT1EPHX2NPC1 | |
| SCHEMBL10223935 | 0.80 | EPHX2 (0.72) | SMN1; SMN2NPSR1EPHX2NPC1RAB9A | |
| SCHEMBL4982564 | 0.76 | MAPT (0.57) | EPHX2NPC1TSHRRAB9AALDH1A1 | |
| SCHEMBL10210850 | 0.75 | SMN1; SMN2 (0.64) | SMN1; SMN2NPSR1EPHX2NPC1RAB9A | |
| SCHEMBL14519207 | 0.75 | EPHX1 (0.70) | SMN1; SMN2NPSR1EPHX2NPC1RAB9A | |
| SCHEMBL11754054 | 0.75 | SMN1; SMN2 (0.63) | SMN1; SMN2NPSR1NPC1HTTRAB9A | |
| SCHEMBL11685462 | 0.75 | SMN1; SMN2 (0.63) | SMN1; SMN2NPSR1NPC1HTTRAB9A | |
| SCHEMBL4984113 | 0.75 | CXCR3 (0.63) | SMN1; SMN2NPSR1EPHX2NPC1TSHR | |
| SCHEMBL4113279 | 0.75 | EPHX2 (0.65) | SMN1; SMN2NPSR1MALT1EPHX2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | SMN1; SMN2 4046/4885NPSR1 55/4885MALT1 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.